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Abstract 
Both astrocytes and microglia are often activated in association with diseases of the central nervous 
system (CNS), including virus-induced neurological disease. Understanding how activation alters 
the transcriptome of these cells may offer valuable insight in regards to how activated cells mediate 
neurological damage. Furthermore, identifying common and unique pathways of gene expression 
during activation may provide new insight into the distinct roles these cells have in the CNS during 
infection and inflammation. In the current study, we utilized microarray analysis to examine the 
response of astrocyte and microglia to specific innate immune stimuli. Since virus infections often 
induce activation of toll-like receptor 7 (TLR7), we used the TLR7 agonist imiquimod that has been 
shown to induce activation of both microglia and astrocytes in vivo and in vitro. We found that 
microglia generate a much stronger response to TLR7 activation than astrocytes, with the 
upregulation and downregulation of substantially more genes in microglia than that observed in 
astrocytes. We identified genes that were uniquely upregulated by each cell type and examined 
these genes for upregulation by other factors including virus infection. These data provide new 
insights into innate immune activation of astrocytes and microglia that will be useful in 
characterizing the cellular responses of these genes during infection or insult of the CNS.  
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1. Introduction 
1.1. Neuroinflammation 
The term neuroinflammation is used to describe the immune responses within the Central Nervous 
System (CNS) associated with a large number of neurodegenerative diseases 
1
. Neuroinflammation 
is a common response to viral, bacterial and parasitic infection or injury of the CNS and is 
dependent on the initiation of innate immune responses 
2-5
. The inflammatory response may induce 
beneficial effects such as phagocytosis of debris and apoptotic cells, initiate repair processes, limit 
virus replication through production of type I interferons and recruitment of virus-specific T cells to 
the CNS 
6, 7
. However, neuroinflammation can also result in production of neurotoxic factors that 
contribute to the development and severity of neurodegenerative pathology and can also lead to the 
recruitment of virus-infected cells to the CNS 
8
. 
The CNS has limited interactions with the peripheral immune system due to the lack of lymphatics 
vessels and the presence of tight junctions at the blood–brain and blood–cerebrospinal fuid (CSF) 
barriers that limit the influx of cells and protein to the CNS 
9-11
. As such, peripheral immune cells 
have limited access to the CNS. In addition, the brain does not have a resident population of 
dendritic cells to trigger innate immune responses. Thus, cells intrinsic to the brain, including brain 
macrophages and microglia and astrocytes play important roles in the innate immune response to 
pathogen infection in the CNS. These cells are often referred to as glia cells, and their activation 
termed gliosis. 
 
1.2. Glial Cells 
Glial cells are defined as the non-neuronal cells of the cells of the CNS and can be divided into two 
groups: microglia and macroglia. Macroglia include oligodendrocytes, the myelin forming cells, 
and astrocytes, the most abundant and heterogeneous population of glial cells, and the major 
‘housekeeping’ cells of the CNS 12. Macroglial cells are derived from the embryonic 
neuroectoderm. Microglia are the resident “immune cell” of the brain and are derived from the yolk 
sac early in development 
13
. 
Despite their differences in origin, astrocytes and microglia are often found activated together in 
cases of neurodegeneration. Proinflammatory cytokines and chemokines produced by both 
astrocytes and microglia are common finding among virus infections in the CNS, including HIV 
infection in adult and pediatric patients. Astrocytes and microglia are recognized as active 
participants in various pathological conditions such as viral, bacterial and parasitic infection or 
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injury of the CNS or chronic neurodegenerative disorders, such as Alzheimer’s disease, Parkinson's 
disease, Multiple Sclerosis and acquired immune deficiency syndrome dementia 
2-5, 14-16
. The strong 
correlation between neurologic disease and the intensity of the innate immune response suggests 
that several proinflammatory cytokines and/or chemokines may contribute to the disease process. 
Astrocytes and microglia often produce different cytokines during virus infections. However, it is 
unclear whether this difference is due to the infection/stimuli or different responses of the cells to 
the same stimuli. 
 
1.3. Microglia 
Although originally thought to be derived from bone marrow monocytes, recent studies demonstrate 
that microglia are derived early during development from immature progenitors in the yolk sac. 
These cells persist in the CNS for the entire life of the organism with only limited turnover from 
bone-marrow derived monocytes 
17
.  
In the healthy mature CNS, microglia have a ramified morphology, characterized by a small soma 
with fine cellular processes. This typical appearance, which is quite different from a classical 
macrophage, has been associated with microglia “resting” state. Infection, trauma, ischemia, 
neurodegenerative diseases, or altered neuronal activity can evoke rapid and profound changes in 
the microglial cell shape, gene expression and the functional behavior which summarily is defined 
as “microglial activation” 18, 19. When microglia becomes activated, they increase the size of their 
cell bodies, retract their processes and take an ameboid or macrophage-like morphology, attracted 
by endogenous and exogenous chemotactic factors using amoeboid-like movements they gather 
around sites of insult. At the site of damage, microglia phagocytize intracellular microorganism, 
removing dying cells and cellular debris 
20, 21
. They also undergo rapid proliferation in order to 
increase their number. This activation may also lead to direct or indirect production of 
proinflammatory cytokines and chemokines which then contribute to the inflammatory 
environment. Chronically activated microglia overproduce soluble inflammatory mediators such as 
tumor necrosis factor (TNF), nictric oxide (NO) and interleukin-1 all of which have been 
demonstrated to enhance inflammation-induced oxidative stress in vulnerable neuronal populations 
22-27
. 
Immune recognition molecules, such as MHC class II, can be identified on ramified (resting) 
microglia in the undisturbed brain, upon injury the molecules are highly upregulated and the 
expression of this complex is essential for interacting with T lymphocytes.
28-31
. 
Recent studies also indicate that microglia support and monitor synaptic function 
32
, and control 
synaptogenesis 
33
. Microglia can also promote tissue repair by secreting growth factors thus 
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facilitate returning to homeostasis 
34
. Thus, microglia are important for CNS development and 
maintenance. 
Therefore, elucidation of molecular regulators of microglial responses that affect neuronal survival 
during chronic inflammatory stress is of great importance as it may reveal opportunities for novel 
anti-inflammatory strategies to prevent or delay onset of chronic neurodegenerative disease.  
 
1.4. Astrocytes 
Astrocytes, the most abundant glial cell are of neuroectodermal origin and are essential for brain 
homeostasis and neuronal function 
35
. Astrocytes function as supportive cells in neural tissue, create 
the brain environment, build up the micro-architecture of the brain parenchyma and are responsible 
for a wide variety of complex and essential functions in the healthy CNS.  
These star-shaped cells have a central cell body and long processes extending in all directions. 
Processes extending from different cells establish contacts with each other via gap junctions 
36
. 
Moreover, their processes envelope synapses formed by neurons and also contact the exterior of 
capillary vessels. Astrocytes form ‘end-feet’ processes which surround blood capillaries and are 
thought to play a role in maintaining the integrity of the BBB. They regulate transendothelial cell 
migration across the blood–brain barrier (BBB) restricting the access of immune cells to the CNS 
parenchyma 
37
. Astrocyte can control CNS homeostasis through the regulation of ion, 
neurotransmitter, metabolites and neuro-hormone concentrations, as well as the production of 
growth factors 
38
. 
Astrocytes are emerging as key players in the regulation of synaptic activity throughout the brain. 
They regulate formation, maturation, maintenance, and stability of synapses thus controlling the 
connectivity of neuronal circuits. Astrocytes secrete numerous factors indispensable for 
synaptogenesis, and without astrocytes, formation of synapses would be greatly depressed
 39-42
. 
Astrocytes control maturation of synapses through several signalling systems. Additionally, 
astrocytes have recently been shown to transmit signals to neurons that directly modulate synaptic 
strength or even contribute to synaptic transmission by release of transmitters that directly stimulate 
postsynaptic neurons 
43
. Astrocytes are also involved in the synthesis and metabolism of 
neurotransmitters, modulating glutamate levels in the extracellular space and preventing glutamate-
induced neurotoxicity 
44, 45
. 
During pathological conditions of the brain, astrocytes are able to respond promptly to neuronal 
injury, undergoing changes in their phenotype. Upon activation, astrocytes increase production of 
glial fibrillary acidic protein (GFAP), undergo process extension and interdigitation, respond to 
protracted stress and insults by up-regulating inflammatory processes. The process by which these 
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cells become activated during infections and the downstream effects of astrocyte activation remain 
important questions in understanding pathogenesis in the CNS, indeed activated astrocytes release a 
wide array of pro-inflammatory molecules, including cytokines and chemokines that contribute to 
neuropathogenesis of CNS infections 
16
. 
 
1.5. Toll-like receptors (TLRs) 
The innate immune system is the major contributor to acute inflammation induced by microbial 
infection or tissue damage. Furthermore, innate immunity is also important for the activation of 
acquired immunity. Inflammatory response are initiated by the recognition of pathogen-associated 
molecular patterns (PAMPs), the molecules associated with groups of pathogens, which are 
recognized by of receptors belonging to multiple receptor families collectively called pattern 
recognition receptors (PRRs) 
46-49
. 
The TLR family is one of the best-characterized PRR families and is responsible for sensing 
invading pathogens outside of the cell and in intracellular endosomes and lysosomes. TLRs are 
conserved type I membrane glycoproteins characterized by N-terminal leucine-rich repeats (LRRs) 
and a transmembrane region followed by a cytoplasmic Toll/IL-1R homology (TIR) domain 
50
. 
TLR expression has been detected in cells of the innate and adaptive immune system and in non-
immune cells.  
Currently, there are at least 11 TLRs identified in humans and 12 TLRs identified in mice 
51
. 
Different TLRs recognize the different molecular patterns of microorganisms and self-components. 
These TLRs can be separated into two broad categories based on their cellular location or their 
signal transduction machinery. TLR1, TLR2, TLR4, TLR5 and TLR6 are localized to the plasma 
membrane and were originally identified as receptors for bacterial. However, several studies have 
shown that TLR2 and TLR4 can contribute to anti-viral responses 
52-56
. 
TLR3, TLR7, TLR8 and TLR9 are primarily located on intracellular membranes and are shuttled 
from the endoplasmic reticulum to the endolysosome where they recognize microbial nucleic acids.  
Activation of these TLRs leads to the production of type I interferons (IFNs) in addition to 
proinflammatory cytokines. 
TLR3 recognizes double stranded RNA (dsRNA) generated during replication of certain RNA 
viruses as well as polyinosinic:polycytidylic acid, termed poly (I:C).  TLR9 recognizes bacterial 
and viral cytosine-phosphate-guanosine (CpG) DNA motifs (unmethylated DNA motifs containing 
CpG nucleotides flanked by 5’ purines and two 3’ pyrimidines) 57, 58.  
TLR7 and TLR8, which are highly similar, recognize guanidine-uridine rich single stranded RNA 
(ssRNA) from certain RNA viruses 
59-61
. 
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TLR7 and TLR8 also recognize a number of synthetic molecules such as imidazoquinolines and 
nucleoside analogues that have been used for anti-viral treatment 
62, 63
. 
In addition to recognizing viral RNA or DNA during virus entry and uncoating in the endosome, 
these endosomal TLRs also sense intracellular virus replication through autophagy of viral nucleic 
acids 
64, 65
. 
Recognition of PAMPs by TLRs leads to transcriptional upregulation of distinct genes, TLRs 
initiate signaling through their cytoplasmic Toll/IL-1R (TIR) domains. These interact with other 
TIR domains such that upon activation, each TLR binds to a specific set of adapter proteins that 
also contain TIR domains. TRL7/9 recognize nucleic acids, and signal via Myeloid differentiation 
factor 88 (MyD88). 
Emerging evidence suggests a role for TLRs in infectious and noninfectious CNS injury 
66-69
. 
The expression of TLRs and related signaling proteins has been demonstrated in all major glial cell 
types, including microglia, astrocytes and oligodendrocytes, as well as a more limited repertoire in 
neurons. Both murine astrocytes and microglia express TLR7 and TLR9 mRNA 
69, 70
. 
Furthermore, both astrocytes and microglia can respond to TLR7 or TLR9 agonist stimulation in 
vitro 
71-73
. Thus, innate immune responses elicited by TLR stimulation may have an important role 
in inducing neuroinflammation during insult or injury to the CNS. 
 
1.6. Expression of PRRs in the Central Nervous System 
Most studies of PRRs have been directed at understanding their function in immune cells, but it is 
also important to understand the expression and function of these receptors in tissue specific 
environments. In the CNS, this includes not only neurons, but also microglia, astrocytes, 
oligodendrocytes, perivascular macrophages, ependymal, endothelial and epithelial cells. These 
cells can mediate the innate immune response to virus infection as well as regulate the trafficking of 
inflammatory cells to the CNS. Thus, there are a number of cell types in the CNS that may 
influence virus infection, but may differ in their response to PRR stimulation compared to bone 
marrow-derived immune cells 
74
.  
Immunofluorescence studies have resulted in limited detection of TLRs in the CNS, with no 
detection of TLR1, TLR3, TLR4 or TLR9 in normal mouse brain 
72
. 
However, RNA analysis and functional studies have demonstrated that multiple cell types in the 
CNS respond to TLR stimulation including glial cells (microglia, astrocytes and oligodendrocytes). 
Microglia express mRNA for all known TLRs 
75-79
. 
Oligodendrocytes also express a number of TLRs and respond to LPS stimulation 
73, 80, 81
. 
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The expression of TLRs by astrocytes appears to vary depending on species and activation state. 
Murine astrocytes express mRNA for TLRs from 1-10, with the exception of TLR8 
82
. 
Human astrocytes express TLR3 mRNA at robust levels, TLR 1, 4, 5, and 9 at low-levels, and TLR 
2, 6, 7, 8, and 10 mRNA at rare-to-undetectable levels by quantitative real-time PCR 
83
. 
Ex vivo analyses of primary astrocyte and microglia cultures demonstrate that both cell types 
respond to multiple TLR agonists through the production of proinflammatory cytokines 
70, 73, 78, 84, 
85
. 
 
1.7. Use of the mouse model of virus infection to study innate immunity in the 
central nervous system 
The activation of astrocytes and microglia, along with increased production of proinflammatory 
cytokines and chemokines is a common response in the CNS to virus infection. Similar 
neuroinflammatory responses are observed in animal models of virus infection. The mouse model 
of virus infection provides a valuable animal model to study the contribution of the innate immune 
response to viral neuropathogenesis because of the ability to use mice deficient in specific PRRs, 
cytokines or cytokine receptors 
86-95
. 
To identify specific patterns of gene expression specific to astrocytes and microglia in the CNS 
following infection, we utilized the mouse model of virus infection. We utilized two different 
mouse models of virus infection; a retrovirus (MuLV) infection model, where the primary cells 
infected are microglia and macrophages, and a La Crosse virus (LACV) infection, where the 
primary infected cells are neurons.  In both model systems, gliosis is associated with pathogenesis. 
 
1.8. La Crosse virus LACV 
La Crosse virus (LACV) is a mosquito-borne pathogen that infects up to 300,000 people in the 
United States and can cause encephalitis in children and young adults 
96
.  
The virus is transmitted by hardwood forest dwelling mosquitoes, Aedes triseriatus, which breed in 
tree holes and outdoor containers. Ae. triseriatus feed on Eastern chipmunks (Tamias striatus 
grinseus) and Eastern gray squirrels (Sciurus carolinensis) which serve as amplifying hosts for 
LACV 
97
. 
Interestingly, the virus can be maintained in the mosquito population in the absence of vertebrate 
hosts by transovarial (vertical) transmission, thus allowing the virus to over-winter in mosquito 
eggs 
98
.  
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The geographic distribution of LAC virus is associated with the distribution of hardwood forests 
and the distribution of the vector, Aedes triseriatus. The virus is transmitted to humans through a 
mosquito bite 
99-101
. 
LACV belongs to the genus Orthobunyavirus, family Bunyaviridae 
102
. Virions are spherical, 80 to 
120 nm in diameter and have a host cell-derived bilipid-layer envelope The virions contain three 
major structural proteins: two envelope glycoproteins, G1 and G2, and a nucleocapsid protein N, 
plus minor quantities of a large or L protein believed to be the viral transcriptase, an RNA-
dependent RNA polymerase. The LACV genome consists of three linear single-stranded, negative-
sense RNA genome segments designated large (L), medium (M), and small (S) 
103
. All three gene 
segments of a virus have the same complementary nucleotides at their 3' and 5' termini. Viral entry 
into its host cell is thought to occur by receptor-mediated endocytosis. All subsequent steps take 
place exclusively in the cytoplasm. After penetration of the host cell, the virion transcriptase is 
activated and transcribes subgenomic mRNAs from each of the three virion RNA segmets while 
still associated with their nucleocapsids. After translation of these mRNAs, replication of the RNA 
can occur and a second round of transcription begins. The L RNA segment codes a single open 
reading frame for the transcriptase (RNA-dependent RNA polymerase) 
104 
the M segment codes a 
single polyprotein (M polyprotein) that is post-translationally processed into two glycoproteins (G1 
and G2), and a non-structural protein (NSM) the S RNA segment codes for the nucleocapsid protein 
(N) and a non-structural protein (NSS) 
105-107
.  
A hallmark of neurological diseases caused by LACV and other encephalitic viruses is the induction 
of neuronal cell death. Innate immune responses have been implicated in neuronal damage. No 
specific therapies or vaccines are available for LACV.  
 
1.9. Retrovirus 
Murine leukemia viruses (MuLVs), are subfamily of the gamma retroviruses. The MuLV family 
can be further divided depending on the type of cellular receptor utilized by the virus, which also 
affects the host range of the virus. For example, ecotropic retroviruses, which primarily infect 
mouse cells, utilize the cationic amino acid transporter (solute carrier family 7 member 1, SLC7A1) 
protein as a receptor. Amphotropic retroviruses, which infect a broad range of species, utilize the 
phosphate transporter solute carrier family 20 member 2 (SLC20A2) protein as a receptor. 
Polytropic as well as xenotropic retroviruses infect cells through the xenotropic/polytropic receptor 
1 (XPR1), a member of the G-protein coupled receptor protein signaling pathway family 
108, 109
. 
Polymorphisms in XPR1 between mammalian species mediate the host range of xenotropic and 
polytropic viruses 
110, 111
.  
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Differences between the subfamilies of MuLVs are also observed with virus infection and 
pathogenesis of the CNS. Ecotropic retroviruses can induce either intracerebral hemorrhages or 
widespread spongiform degeneration depending on determinants in the ecotropic envelope protein 
112, 113
. In contrast, the brain pathology following infection with neurovirulent polytropic 
retroviruses is more limited and primarily consists of reactive astrogliosis, white matter microglial 
infection with microgliosis and microglial nodules. There is only minimal vacuolation and only 
occasional neuronal death. Polytropic retrovirus infection of the CNS has some similarities with 
HIV-encephalopathy as HIV infection of the CNS also induces reactive astrogliosis, microglia 
nodules without an extensive infiltration of inflammatory cells from outside the CNS . 
In the brain, the polytropic viruses productively infect endothelia, microglia, and macrophages with 
only rare infection of oligodendrocytes. Polytropic retroviruses do not productively infect neurons 
or astrocytes indicating that effects on these cell types are indirect. 
The most well-studied neurovirulent polytropic retrovirus is a molecular clone, Fr98. Infection with 
Fr98 induces neurologic disease in 100% of newborn Inbred Rocky Mountain White (IRW) or 
129S6 mice within 2–4 weeks post-infection. Mice have initial clinical signs of tremors and hind 
limb weakness, followed by ataxia, seizures, and ultimately death 
114, 115
. As all animals develop 
neurologic disease, infecting knockout mice with Fr98 provides a useful method to determine if 
individual inflammatory genes affect the disease process. In this study, we utilized neurovirulent 
chimeric viruses BE that differ by only a few amino acid residues in envelope regions. The 
construction of chimeric virus clones for BE has been previously published 
116, 117
.  
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Aim of the thesis 
In the CNS, glial cells not only serve supportive and nutritive roles for neurons, but also respond to 
protracted stress and insults by up-regulating inflammatory processes. Reactive glial cells produce a 
wide array of pro-inflammatory molecules, including, cytokines and chemokines. The complexity 
of studying glial activation in vivo has led to the widespread adoption of in vitro approaches, for 
example the use of the TLRs as an experimental model of glial activation. 
In the present study, we identify genes that are differentially expressed between astrocytes and 
microglia when they are activated by the innate immune response. Understanding how activation 
alters the normal function of microglia and astrocytes and how the expression of these genes 
influences virus infection and pathogenesis in the CNS is of great importance as it may reveal 
opportunities for novel anti-inflammatory strategies for therapeutic intervention to prevent or delay 
onset of chronic neurodegenerative disease. Furthermore, identifying common and unique pathways 
of gene expression during activation may provide new insight into the distinct roles these cells have 
in the CNS during infection and inflammation. 
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2. Materials and methods 
2.1. TLR Agonists 
The TLR7 agonist imiquimod (R837) and TLR9 agonist type B CpG-ODN 1826 [5’-TCC ATG 
ACG TTC CTG ACG TT-3’] were purchased from InvivoGen.  All the agonists were suspended in 
endotoxin-free water, aliquoted, and stored at -20°C. Just before use, agonists were diluted in media 
specific for either astrocytes or microglia. 
 
2.2. Media 
Astrocyte cultures were maintained in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) 
containing 4,500 mg glucose/L, 110 mg sodium pyruvate/L, 0.584 g L-glutamine/L, supplemented 
with 10% inactivated fetal bovine serum (Hyclone) and 1% penicillin-streptomycin (Gibco).  
Microglia-specific media contained 20% LADMAC culture supernatant (mouse bone marrow cells 
producing macrophage colony stimulating factor/M-CSF) in RNA Isolation and Quantitative Real-
Time RT-PCR addition to the media used for astrocyte cultures. 
 
2.3. Isolation and Culturing of Cortical Astrocytes and Microglia by Percoll 
Gradient Method 
Astrocyte and microglia cultures were prepared from the brain cortex of 1-2 day old Inbred Rocky 
Mountain White (IRW) mice. Mice were anesthetized, brain tissue removed, and placed in ice cold 
phosphate buffered saline (PBS). Hind brains, mid brains, and meninges were dissected out. 
Cerebral cortices were transferred to a 15-mL conical tube containing 2% glucose in PBS and made 
into single cell suspension. Cells were pelleted by centrifugation at 500 g for 5 min. Cells from two 
brain cortices were suspended in 2 mL of 70% percoll and transferred to the bottom of 30% and 0% 
percoll gradient. The gradients were centrifuged at 500g for 20 min.  Cells between 0% and 30% 
percoll layers were rich in astrocytes and were seeded at 2 x 10
5
 cells in Primaria T-25 flasks (BD 
Bioscience) containing astrocyte specific media. The microglia cell populations collected between 
30% and 70% percoll layers were seeded at 5 x 10
5
 in T-25 flasks containing microglia-specific 
media. When cells became confluent, after 7–10 days of culture, flasks containing astrocyte rich 
cells (0/30 fraction) were orbitally shaken overnight at 250 rpm to remove contaminating microglia 
and oligodendrocytes.  Astrocytes were then treated with 0.25% Trypsin-EDTA (Gibco), reseeded 
in Corning 12-well cell bind plates (ISC BioExpress). Microglia were removed from confluent T-25 
flasks using a cell scrapper and reseeded in 12-well cell bind plates. 
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2.4. Stimulation of Astrocyte and Microglia Cultures with Imiquimod or CpG-
ODN 
Astrocytes and microglia were treated with either 5 µM imiquimod or 80 nM of CpG-ODN 1826 or 
both for 3, 6, 12, 24 or 48h. 
 
2.5. RNA Isolation and Quantitative Real-Time RT-PCR 
At specified time-points post stimulation astrocyte and microglia cells were lysed and processed for 
RNA extraction using a mini RNA isolation kit (Zymo Research) following manufacturer’s 
instructions. RNA was treated with DNAse I (Ambion) for 30 min at 37°C to remove any genomic 
DNA contamination and purified using RNA cleanup columns (Zymo Research). 
cDNA was generated using an iScript reverse transcription kit (Bio-Rad) following manufacturer’s 
instructions and included DNA contamination controls that did not undergo reverse transcription. 
cDNA samples were diluted fivefold in RNase-free water after reverse transcription, prior to use in 
quantitative real-time PCR reaction. All the real-time PCR reactions were performed using a 7900 
Applied Biosystems PRISM instrument. All the samples were run in triplicate on a 384-well plate. 
Each reaction contained iTaq SYBR green supermix with ROX (Bio-Rad), 0.5 µM forward and 
reverse primers, approximately 10 ng of cDNA template and nuclease-free water. Primers were 
confirmed to be specific for the gene of interest.  No homology to other genes was detected by blast 
analysis of primers against the National Center for Biotechnology Information (NCBI) database. 
RNA that did not undergo reverse transcription and water were used as negative controls. 
Dissociation curves were used to confirm amplification of a single product for each primer pair per 
sample. 
Data were calculated as the difference in CT value (log2) for Gapdh minus the CT value of the gene 
of interest for each sample (ΔCT=CT Gapdh −CT gene of interest) to control for variations in RNA 
amounts in each sample. The data are presented as the fold expression of the gene of interest 
relative to Gapdh. For example, a value of one indicates the same level of mRNA expression as 
Gapdh (ΔCT=0), whereas a value of two indicates a two folds higher level of mRNA expression 
than GAPDH (ΔCT=1). 
 
2.6. Microarray analysis 
Wells from six well plates of microglia or astrocytes were randomly assigned to either mock or 
imiquimod stimulation groups. Six replicates per group were used for microarray analysis. 
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Microarray analysis was performed by the Genomics Unit of the Research and Technologies 
branch, NIAID using GeneChip Mouse Gene 1.0 ST Array from Affymetrix. 
 
2.7. Immunohistochemistry using fluorescent secondary antibodies 
The half of the brain tissue that was formalin fixed was further divided into four coronal and sagittal 
sections, embedded in paraffin, and cut in 4 m sections. Slides were rehydrated, and antigen 
retrieval was performed by incubating slides in 0.018 M citric acid and 8.2 M sodium citrate 
dihydrate, pH 6.0, for 20 min at 120°C.  Slides were then incubated in 0.2% fish skin gelatin (FSG) 
(Sigma-Aldrich, St. Louis, MO) in phosphate-buffered saline (PBS). Sections were blocked for a 
minimum of 30 min with blocking solution consisting of 2% donkey serum (Sigma), 1% bovine 
serum albumin (Sigma), 0.05% FSG, 0.1% Triton X-100 (Sigma), and 0.05% Tween 20 (Bio-Rad) 
in PBS.  Slides were incubated in primary antibodies at 4°C overnight. For the detection of virus-
infected cells, a 500-fold dilution of goat polyclonal anti-gp70 was used (10). Primary antibodies 
were detected using Alexa Fluor 594-conjugated donkey anti-rabbit IgG, Alexa-Fluor488-
conjugated goat anti-mouse IgG, Alexa Fluor 488-conjugated chicken anti-goat IgG, biotin-labeled 
goat anti-rabbit IgG, and Alexa Fluor 594 conjugated to streptavidin (Invitrogen). All sections were 
counterstained with 100 ng/ml DAPI (4,6-diamidino-2-phenylindole; Molecular Probes) for 20 min. 
Slides were mounted with ProLong Gold antifade reagent (Molecular Probes). Additional slides 
were incubated with individual primary antibodies or no primary antibodies prior to incubation with 
secondary antibodies to confirm the lack of nonspecific staining or cross-reactivity. Slides from not 
infected mice were used as a negative control. Digital images were captured using NIS Elements 
software (Nikon) and compiled using Canvas XI software (ACD Systems). For counting positive 
cells in each field, images were captured, using NIS Elements software, of the appropriate regions 
of tissue in a blind fashion. The number of positive cells per image per 200field of view was 
recorded. Multiple images from at least three mice per group were used for analysis. 
 
2.8. Immunocytochemistry using fluorescent secondary antibodies 
Glia cultures in 8-chamber slides (BD Biocoat) were fixed in 4% paraformaldehyde (Electron 
Microscopy Sciences) and permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) and 0.1% 
sodium citrate (Sigma- Aldrich) in 13 PBS for 30 min. Cells were then treated with 0.1M glycine 
for 30 min and incubated with blocking solution containing 2% donkey serum (Millipore), 1% BSA 
(Sigma-Aldrich), 0.1% cold fish skin gelatin (Sigma- Aldrich), 0.1% Triton X-100, 0.05% Tween 
20 (Sigma- Aldrich) in PBS for 30 min. Cells were incubated with primary antibodies for 30 min at 
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room temperature. Cells were then incubated with goat anti-mouse Alexa Fluor 488 (Invitrogen) or 
goat anti-rabbit Alexa Fluor 555 (Invitrogen) for 30 min at room temperature. Finally, slides were 
mounted in Fluorogel II with DAPI (Electron Microscopy Sciences). All images were taken using a 
Nikon Eclipse 55i fluorescent microscope. 
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3. Results 
3.1. Comparison of gene profile between microglia and astrocytes following 
TLR7-induced activation 
To directly compare how TLR7 activation altered the gene expression profile in astrocytes and 
microglia, we used primary cultures of both cells types generated from neonatal mice.  Purity of 
cultures was greater than 99% as determined by flow cytometry. A time point of 6 hr post 
stimulation was chosen as this time point correlates with high cytokine mRNA production. Analysis 
of microarray data indicated a total of 260 genes that were upregulated by TLR7 ligand stimulation 
in either microglia or astrocytes, and 124 genes that were down regulated. Most of these genes were 
up or down regulated only in microglia (Tables 1, Sup. Table 1), while a much smaller subset was 
found regulated in both cell types (Table 2). Only 9 genes were upregulated only in astrocytes 
(Table 3). This indicates that microglia generate a more robust gene response to TLR7 stimulation 
compared to astrocytes, both in the number of genes whose mRNA expression is induced as well as 
the overall level or mRNA upregulation. 
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Table 1. Top 40 genes upregulated or down-regulated in microglia only. 
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Gene Symbol Gene Description Astrocyte Microglia
Marco macrophage receptor with collagenous structure 1,32 17,20
Ccl5 chemokine (C-C motif) ligand 5 1,01 14,66
Il1f9 interleukin 1 family, member 9 1,17 14,56
Saa3 serum amyloid A 3 1,10 13,03
Nos2 nitric oxide synthase 2, inducible 1,61 11,22
Gbp2 guanylate binding protein 2 1,86 10,00
Ptges prostaglandin E synthase 1,39 9,32
H2-M2 histocompatibility 2, M region locus 2 1,26 9,05
Traf1 TNF receptor-associated factor 1 1,88 9,02
EG622976 predicted gene, EG622976 1,66 7,94
Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 1,27 7,59
Cd38 CD38 antigen 1,41 7,23
Ccrl2 chemokine (C-C motif) receptor-like 2 1,64 5,60
Jak2 Janus kinase 2 1,74 5,48
Lox lysyl oxidase 1,57 5,42
Gbp3 guanylate binding protein 3 1,40 5,12
Cfb complement factor B -1,01 5,04
Niacr1 niacin receptor 1 1,34 4,98
Il13ra2 interleukin 13 receptor, alpha 2 1,10 4,94
Rsad2 radical S-adenosyl methionine domain containing 2 1,58 4,92
Cd40 CD40 antigen 1,27 4,80
Gadd45b growth arrest and DNA-damage-inducible 45 beta 1,24 4,77
Met met proto-oncogene 1,04 4,71
Rab11fip1 RAB11 family interacting protein 1 (class I) 1,13 4,68
C3 complement component 3 1,15 4,20
Cd274 CD274 antigen 1,77 4,19
Il10 interleukin 10 1,14 4,09
Fabp3 fatty acid binding protein 3, muscle and heart 1,13 4,03
Mmp14 matrix metallopeptidase 14 (membrane-inserted) 1,13 3,98
Nlrp3 NLR family, pyrin domain containing 3 1,86 3,95
Hp haptoglobin 1,31 3,94
Fabp3 fatty acid binding protein 3, muscle and heart 1,16 3,93
Edn1 endothelin 1 1,20 3,86
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 1,31 3,77
Ccl22 chemokine (C-C motif) ligand 22 1,23 3,76
Hck hemopoietic cell kinase 1,41 3,75
Il18 interleukin 18 1,25 3,67
D16Ertd472e DNA segment, Chr 16, ERATO Doi 472, expressed 1,23 3,65
Ak3l1 adenylate kinase 3-like 1 1,16 3,64
Lztfl1 leucine zipper transcription factor-like 1 1,12 3,60
Zfp558 zinc finger protein 558 -1,04 3,58
Mpa2l macrophage activation 2 like 1,74 3,56
Socs3 suppressor of cytokine signaling 3 1,23 3,55
Zc3h12c zinc finger CCCH type containing 12C 1,73 3,54
Slc7a11 solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 ,65 3,51
Slco3a1 solute carrier organic anion transporter family, member 3a1 1,18 3,49
Ifit3 interferon-induced protein with tetratricopeptide repeats 3 1,00 3,49
Ifit2 interferon-induced protein with tetratricopeptide repeats 2 1,05 3,46
Mmp13 matrix metallopeptidase 13 1,24 3,39  
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Gene Symbol Gene Description Astrocyte Microglia
Dcbld2 discoidin, CUB and LCCL domain containing 2 1,18 3,32
Dusp1 dual specificity phosphatase 1 -1,03 3,31
Ifi202b interferon activated gene 202B 1,13 3,30
Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 1,06 3,27
Pstpip2 proline-serine-threonine phosphatase-interacting protein 2 1,47 3,16
Pde4b phosphodiesterase 4B, cAMP specific 1,52 3,13
AA467197 expressed sequence AA467197 1,52 3,10
Gpd2 glycerol phosphate dehydrogenase 2, mitochondrial -1,04 3,07
Gm129 gene model 129, (NCBI) -1,12 3,07
Phlda1 pleckstrin homology-like domain, family A, member 1 1,46 3,07
Cd300e CD300e antigen 1,10 3,05
Upp1 uridine phosphorylase 1 1,20 3,03
Mx2 myxovirus (influenza virus) resistance 2 1,07 3,02
Ebi3 Epstein-Barr virus induced gene 3 1,30 2,99
Mmp9 matrix metallopeptidase 9 1,43 2,98
Pilrb1 paired immunoglobin-like type 2 receptor beta 1 1,20 2,95
Abcc5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1,13 2,95
Egln3 EGL nine homolog 3 (C. elegans) 1,05 2,90
Slc6a12 solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12 1,07 2,90
Isg15 ISG15 ubiquitin-like modifier 1,07 2,88
Mmp3 matrix metallopeptidase 3 1,14 2,88
Zc3h12c zinc finger CCCH type containing 12C 1,43 2,87
Adm adrenomedullin 1,17 2,86
Dusp16 dual specificity phosphatase 16 1,20 2,86
Ptx3 pentraxin related gene 1,19 2,82
Lif leukemia inhibitory factor 1,36 2,81
Lztfl1 leucine zipper transcription factor-like 1 1,20 2,78
Ptafr platelet-activating factor receptor -1,04 2,77
Tet2 tet oncogene family member 2 1,02 2,75
Rilpl2 Rab interacting lysosomal protein-like 2 1,31 2,75
Bnip3 BCL2/adenovirus E1B interacting protein 3 1,14 2,74
Adora2b adenosine A2b receptor 1,25 2,73
Rapgef2 Rap guanine nucleotide exchange factor (GEF) 2 1,02 2,68
Inhba inhibin beta-A 1,15 2,67
Thbs1 thrombospondin 1 -1,06 2,67
Fam102b family with sequence similarity 102, member B -1,06 2,66
Slfn8 schlafen 8 1,27 2,66
Robo2 roundabout homolog 2 (Drosophila) 1,01 2,65
Lix1 limb expression 1 homolog (chicken) 1,01 2,63
F10 coagulation factor X 1,02 2,58
Epha4 Eph receptor A4 -1,07 2,53
Has1 hyaluronan synthase1 -1,01 2,52
Ift57 intraflagellar transport 57 homolog (Chlamydomonas) 1,06 2,51
Csf3 colony stimulating factor 3 (granulocyte) 1,08 2,50
Il1rn interleukin 1 receptor antagonist 1,16 2,49
Peg10 paternally expressed 10 -1,17 2,49
Ak3l1 adenylate kinase 3-like 1 1,03 2,47
Acp5 acid phosphatase 5, tartrate resistant 1,11 2,45
Socs3 suppressor of cytokine signaling 3 1,08 2,41
Olr1 oxidized low density lipoprotein (lectin-like) receptor 1 1,17 2,41  
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Gene Symbol Gene Description Astrocyte Microglia
Nampt nicotinamide phosphoribosyltransferase 1,06 2,40
Bnip3 BCL2/adenovirus E1B interacting protein 3 1,08 2,39
Mx1 myxovirus (influenza virus) resistance 1 1,10 2,39
Flnb filamin, beta -1,01 2,38
Ext1 exostoses (multiple) 1 1,14 2,37
Cav1 caveolin 1, caveolae protein -1,08 2,37
Prelid2 PRELI domain containing 2 1,12 2,34
Ifi204 interferon activated gene 204 1,15 2,34
Apbb3 amyloid beta (A4) precursor protein-binding, family B, member 3 1,01 2,34
Cdc42ep2 CDC42 effector protein (Rho GTPase binding) 2 1,00 2,33
Gyk glycerol kinase 1,11 2,31
Gys1 glycogen synthase 1, muscle 1,08 2,28
Agtrap angiotensin II, type I receptor-associated protein 1,06 2,27
Ppap2a phosphatidic acid phosphatase type 2A 1,06 2,25
Ass1 argininosuccinate synthetase 1 1,10 2,24
Vcan versican 1,05 2,23
Procr protein C receptor, endothelial 1,07 2,22
Ube2e2 ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, yeast) -1,03 2,18
Treml4 triggering receptor expressed on myeloid cells-like 4 1,01 2,10
Tmem2 transmembrane protein 2 1,00 2,07
Eif2c3 eukaryotic translation initiation factor 2C, 3 1,01 2,05
Camp cathelicidin antimicrobial peptide 1,02 2,04
Nav2 neuron navigator 2 -1,01 -2,01
Nt5e 5' nucleotidase, ecto 1,02 -2,05
Tec tec protein tyrosine kinase -1,03 -2,08
Etv5 ets variant gene 5 -1,04 -2,09
Cenph centromere protein H -1,01 -2,09
Slc36a1 solute carrier family 36 (proton/amino acid symporter), member 1 -1,01 -2,09
Dkc1 dyskeratosis congenita 1, dyskerin homolog (human) 1,00 -2,10
Uhrf1 ubiquitin-like, containing PHD and RING finger domains, 1 -1,02 -2,12
Dnajc9 DnaJ (Hsp40) homolog, subfamily C, member 9 1,01 -2,12
Lrrc33 leucine rich repeat containing 33 -1,05 -2,16
Mcm3 minichromosome maintenance deficient 3 (S. cerevisiae) 1,08 -2,17
Epas1 endothelial PAS domain protein 1 -1,06 -2,17
EG574403 predicted gene, EG574403 -1,05 -2,17
Arhgef7 Rho guanine nucleotide exchange factor (GEF7) -1,06 -2,19
Enc1 ectodermal-neural cortex 1 -1,09 -2,20
Kctd12b potassium channel tetramerisation domain containing 12b -1,04 -2,21
Tmem173 transmembrane protein 173 1,03 -2,23
Rbl1 retinoblastoma-like 1 (p107) -1,10 -2,23
Lrp12 low density lipoprotein-related protein 12 -1,09 -2,24
Rmi1 RMI1, RecQ mediated genome instability 1, homolog (S. cerevisiae) -1,10 -2,26
Cugbp2 CUG triplet repeat, RNA binding protein 2 -1,13 -2,27
Tnfrsf23 tumor necrosis factor receptor superfamily, member 23 1,00 -2,27
Chek1 checkpoint kinase 1 homolog (S. pombe) -1,04 -2,28
Cdca7l cell division cycle associated 7 like 1,04 -2,28
Hyal1 hyaluronoglucosaminidase 1 -1,04 -2,33
Xylt1 xylosyltransferase 1 -1,07 -2,34
Prim1 DNA primase, p49 subunit -1,09 -2,34
Cenpk centromere protein K -1,11 -2,35  
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Gene Symbol Gene Description Astrocyte Microglia
Wdhd1 WD repeat and HMG-box DNA binding protein 1 -1,05 -2,39
Apobec1 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 -1,14 -2,42
Arhgap18 Rho GTPase activating protein 18 -1,13 -2,42
Msh2 mutS homolog 2 (E. coli) 1,01 -2,48
Atp6v0a1 ATPase, H+ transporting, lysosomal V0 subunit A1 -1,05 -2,56
Fat3 FAT tumor suppressor homolog 3 (Drosophila) 1,04 -2,57
Fat3 FAT tumor suppressor homolog 3 (Drosophila) -1,20 -2,57
Gins1 GINS complex subunit 1 (Psf1 homolog) -1,09 -2,60
Cd180 CD180 antigen -1,06 -2,60
Mcm4 minichromosome maintenance deficient 4 homolog (S. cerevisiae) -1,06 -2,64
Fat3 FAT tumor suppressor homolog 3 (Drosophila) -1,10 -2,64
Mtss1 metastasis suppressor 1 -1,23 -2,65
Tcf7l2 transcription factor 7-like 2, T-cell specific, HMG-box -1,14 -2,67
Rcbtb2 regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 2 -1,17 -2,71
Zdhhc14 zinc finger, DHHC domain containing 14 -1,16 -2,72
Pola1 polymerase (DNA directed), alpha 1 1,01 -2,75
Vps13c vacuolar protein sorting 13C (yeast) -1,23 -2,80
Ptgs1 prostaglandin-endoperoxide synthase 1 -1,14 -2,81
Adrb2 adrenergic receptor, beta 2 -1,04 -2,82
Pdgfc platelet-derived growth factor, C polypeptide -1,28 -2,85
Fgd4 FYVE, RhoGEF and PH domain containing 4 -1,07 -2,86
Arap2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 1,03 -2,92
Mfsd6 major facilitator superfamily domain containing 6 -1,10 -2,95
Hells helicase, lymphoid specific -1,03 -2,96
Fat3 FAT tumor suppressor homolog 3 (Drosophila) -1,18 -3,07
Itga8 integrin alpha 8 -1,02 -3,13
Gmnn geminin -1,20 -3,20
Sesn1 sestrin 1 -1,10 -3,22
Ivns1abp influenza virus NS1A binding protein -1,03 -3,39
Slc37a2 solute carrier family 37 (glycerol-3-phosphate transporter), member 2 -1,23 -3,44
Abcd2 ATP-binding cassette, sub-family D (ALD), member 2 -1,28 -3,67
Ccnd1 cyclin D1 -1,04 -3,84
Mcm6 minichromosome maintenance deficient 6 (MIS5 homolog, S. pombe) (S. cerevisiae) -1,06 -3,85
Plau plasminogen activator, urokinase -1,50 -4,12
Tmem154 transmembrane protein 154 -1,38 -7,64
Rgs2 regulator of G-protein signaling 2 -1,93 -8,90  
 
Sup. Table 1: Genes upregulated or down-regulated in microglia only. 
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Gene Symbol Gene Description Microglia Astrocyte
Il6 interleukin 6 52,46 4,36
Il1a interleukin 1 alpha 26,11 12,58
Il1b interleukin 1 beta 29,52 5,26
Cd69 CD69 antigen 22,14 10,43
Il12b interleukin 12b 22,57 3,65
AW112010 expressed sequence AW112010 20,74 2,49
Cxcl3 chemokine (C-X-C motif) ligand 3 18,97 3,00
Ptgs2 prostaglandin-endoperoxide synthase 2 19,11 2,43
Irg1 immunoresponsive gene 1 15,91 5,21
Cxcl2 chemokine (C-X-C motif) ligand 2 10,86 9,59
Acpp acid phosphatase, prostate 16,60 2,30
Zfp811 zinc finger protein 811 11,46 4,70
Fpr1 formyl peptide receptor 1 9,44 6,10
Gbp5 guanylate binding protein 5 10,54 4,20
Ccl3 chemokine (C-C motif) ligand 3 4,25 9,42
Tnf tumor necrosis factor 5,56 4,44
Clec4a1 C-type lectin domain family 4, member a1 7,38 2,40
Cxcl10 chemokine (C-X-C motif) ligand 10 4,63 4,83
Cxcl1 chemokine (C-X-C motif) ligand 1 7,16 2,27
Clec4e C-type lectin domain family 4, member e 3,54 5,25
Slamf7 SLAM family member 7 5,45 3,06
Tnfrsf1b tumor necrosis factor receptor superfamily, member 1b 5,50 2,99
Irak3 interleukin-1 receptor-associated kinase 3 5,30 3,04
Tlr1 toll-like receptor 1 5,24 3,07
Malt1 mucosa associated lymphoid tissue lymphoma translocation gene 1 5,45 2,65
Sla src-like adaptor 5,27 2,41
Gpr84 G protein-coupled receptor 84 4,36 3,11
Dgkh diacylglycerol kinase, eta 4,92 2,23
Nfkbiz nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 4,53 2,43
Siglece sialic acid binding Ig-like lectin E 4,28 2,38
Batf basic leucine zipper transcription factor, ATF-like 3,66 2,72
Tnfaip2 tumor necrosis factor, alpha-induced protein 2 2,95 3,35
Ppfibp2 protein tyrosine phosphatase, receptor-type, F interacting protein, binding protein 2 4,17 2,09
Acsl1 acyl-CoA synthetase long-chain family member 1 3,87 2,37
Casp4 caspase 4, apoptosis-related cysteine peptidase 3,74 2,23
Birc3 baculoviral IAP repeat-containing 3 3,48 2,18
Ccl4 chemokine (C-C motif) ligand 4 3,08 2,26
AI504432 expressed sequence AI504432 2,61 2,50
Tlr2 toll-like receptor 2 2,18 2,89
Nfkbia nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 2,72 2,23
Gch1 GTP cyclohydrolase 1 2,65 2,07
Pik3ap1 phosphoinositide-3-kinase adaptor protein 1 2,59 2,09
Ms4a6c membrane-spanning 4-domains, subfamily A, member 6C 2,04 2,52
Pilra paired immunoglobin-like type 2 receptor alpha 2,23 2,01
Havcr2 hepatitis A virus cellular receptor 2 -2,41 -2,07
Cx3cr1 chemokine (C-X3-C) receptor 1 -3,93 -2,02
Hpgd hydroxyprostaglandin dehydrogenase 15 (NAD) -3,40 -2,69
Gcnt1 glucosaminyl (N-acetyl) transferase 1, core 2 -7,19 -2,61
Rasgrp3 RAS, guanyl releasing protein 3 -8,58 -3,01  
 
Tab 2: Genes induced in both microglia and astrocytes. 
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Gene Symbol Gene Description Microglia Astrocyte
Ccl2 chemokine (C-C motif) ligand 2 1,20 4,55
Stap1 signal transducing adaptor family member 1 1,56 3,06
Rapgef5 Rap guanine nucleotide exchange factor (GEF) 5 1,13 2,51
BC023105 cDNA sequence BC023105  // cDNA sequence BC023105 1,14 2,22
Clec12a C-type lectin domain family 12, member a 1,53 2,17
Ccl7 chemokine (C-C motif) ligand 7 1,29 2,14
Elovl7 ELOVL family member 7, elongation of long chain fatty acids (yeast) 1,49 2,13
Cxcl11 chemokine (C-X-C motif) ligand 11 1,30 2,11
Plek pleckstrin 1,50 2,08  
 
Tab 3: Genes upregulated or down-regulated in astrocytes only. 
 
3.2. Analysis of gene expression by real-time PCR analysis 
Many of the genes induced TLR7 stimulation of microglia and astrocytes have already been 
described as being produced by these cells following TLR, bacterial or viral activation. One of the 
focuses of the current microarray study was to identify new markers of microglia and astrocyte 
activation that could be used for future studies. Therefore, we selected several genes that were 
either induced only by microglia, only by astrocytes or induced by both for further analysis (Table 
4). Real-time PCR detection of gene expression was more sensitive than that observed with 
microarray when calculated as fold change relative to mock stimulated controls. Interestingly, this 
lead to fold changes being detected in both microglia and astrocyte populations. Of the eight genes 
analyzed that were detected only in stimulated microglia, seven were found induced by greater than 
two fold by TLR7 stimulation of astrocytes and only five of these were upregulated at a much 
higher level in microglia than in astrocytes (Table 4). Two of the four genes (Cxc1ll and 
BC023105) upregulated in astrocytes were also found to be upregulated in microglia, while the 
other two genes (Elovl7 and Rapgef5) remained upregulated greater than 2 fold in astrocytes only.  
Thus, real-time PCR analysis of gene expression was more sensitive in detecting gene upregulation 
than microarray analysis, particularly for astrocytes. Furthermore, the ratio of fold gene expression 
relative to mock-stimulated controls was generally higher as detected by real-time PCR analysis. 
However, the genes found upregulated by microarray analysis were also upregulated as determined 
by real-time PCR indicating that these genes may be useful to study microglia and astrocyte 
activation. 
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Table 5.  Comparison of gene expression between microarray and real-time PCR
Gene micro astro Difference micro astro Difference
   Microglia Marco 17,2 1,3 13,0 562,0       68,9         8,16
Saa3 13,0 1,1 11,8 3.075,7    186,9       16,46
Gbp2 10,0 1,9 5,4 31,7         8,2            3,88
Traf1 9,0 1,9 4,8 158,8       6,8            23,29
Ifi202b 3,3 1,1 2,9 4,2            1,8            2,35
Ifit1 3,8 1,3 2,9 5,0            5,6            0,88
Nlrp3 3,9 1,9 2,1 7,4            19,9         0,37
Zc3h12c 3,5 1,7 2,0 5,0            6,7            0,75
      Both AW112010 20,7 2,5 8,3 106,2       55,5         1,91
Ptgs2 (Cox 2) 19,1 2,4 7,9 30,6         4,4            6,95
Irg1 15,9 5,2 3,1 193,9       63,2         3,07
Gbp5 10,5 4,2 2,5 443,3       28,2         15,74
Cd69 22,1 10,4 2,1 37,7         205,0       0,18
Nfkbiz 4,5 2,4 1,9 28,2         14,2         1,98
Tnfrsf1b 5,5 3,0 1,8 4,7            10,3         0,46
Malt1 5,5 3,1 1,8 11,4         8,5            1,34
Irak3 5,3 3,0 1,7 7,1            16,0         0,44
Casp4 3,7 2,2 1,7 7,3            4,7            1,55
Birc3 3,5 2,2 1,6 4,4            6,4            0,69
Fpr1 9,4 6,1 1,5 79,2         40,2         1,97
Gpr84 4,4 3,1 1,4 21,2         14,9         1,43
Tnfaip2 2,9 3,3 0,9 2,9            13,6         0,22
 Astrocytes Elovl7 1,5 2,1 0,7 1,9            4,4            0,43
Cxcl11 1,3 2,1 0,6 61,7         20,2         3,06
BC023105 1,1 2,2 0,5 31,9         6,6            4,84
Rapgef5 1,1 2,5 0,4 0,9            3,1            0,29
microarray
imiquimod imiquimod (fold)
real time
 
 
Tab 4: Comparison of gene expression between microarray and real-time PCR. 
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Fig. 1: Comparison of TLR7 stimulation in microglia and astrocytes. Primary cortical cultures were 
generated as described in materials and methods. Glial cells were stimulated with 5 µM imiquimod. 
RNA was isolated from cells at indicated times post stimulation. RNA samples were processed for 
real-time quantitative RT-PCR analysis. Data were calculated relative to the expression of Gapdh 
mRNA and then compared as fold change relative to the average of mock infected controls. 
 
3.3. Gene expression pattern similar following stimulation of another endosomal 
receptor, TLR9 
To determine if the above genes were a common response to TLR-induced activation, we analyzed 
microglia and astrocytes stimulated with the TLR9 ligand, unmethylated CpG-ODN. TLR9 can be 
stimulated by both bacterial or DNA viral infections, both of which can infect the CNS and induce 
meningitis. TLR9-induced activation of microglia and astrocytes induced a very similar response to 
TLR7-induced activation, with the upregulation of mRNA expression for all analyzed genes except 
Ifi202b mRNA in astrocytes and Elvovl7 and Rapgef5 mRNA in microglia (Fig. 2, Table 5). 
Comparison between TLR7 vs TLR9 stimulation indicated two genes in microglia that were 
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induced at a two-fold or more greater level by TLR7 stimulation (Saa3 and Traf1) and four genes 
induced at a greater level by TLR9 stimulation (Ifit1, Nlrp3, Cd69, BC023105). TLR7 stimulation 
induced stronger responses than TLR9 stimulation in astrocytes with 12 genes induced at a two-fold 
greater level (Table 6). Thus, TLR9-induced activation of microglia and astrocytes induced a 
similar gene profile compared to TLR7-induced activation, although, the fold induction varied 
between the two stimuli. 
 
 
Tab. 5: Gene expression following TLR9 ligand stimulation. Comparison of gene expression 
between Imiquimod and CpG-ODN stimulation. 
 
Imiquimod/CpG-ODN
Gene micro astro Difference microglia astrocytes
 Microglia Marco 620,0       26,3         23,6             0,91 2,62
Saa3 692,9       45,8         15,1             4,44 4,08
Gbp2 25,5         3,8            6,7                1,24 2,13
Traf1 74,8         2,7            27,4             2,12 2,50
Ifi202b 6,1            1,2            5,0                0,69 1,48
Ifit1 20,3         2,5            8,1                0,25 2,23
Nlrp3 15,4         10,0         1,6                0,48 1,99
Zc3h12c 3,1            3,8            0,8                1,65 1,78
    Both AW112010 110,3       14,3         7,7                0,96 3,89
Ptgs2 (Cox 2) 18,8         2,2            8,7                1,62 2,03
Irg1 220,8       27,7         8,0                0,88 2,28
Gbp5 268,8       10,8         24,9             1,65 2,61
Cd69 126,1       89,9         1,4                0,30 2,28
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CpG-ODN (fold)
 30 
 
Fig. 2: Analysis of mRNA expression in TLR7/9 stimulated microglia and astrocyte. Comparison 
of mRNA expression of BC023105, Cxcl11, Elovl7 and Rapgef5 by astrocytes and microglia. 
Primary cortical cultures were generated as described in materials and methods. Glial cells were 
stimulated with 5 µM imiquimod or 80 nM CpGODN 1826. RNA was isolated from cells at 6 hps. 
RNA samples were processed for real-time quantitative RT-PCR analysis. Data were calculated 
relative to the expression of Gapdh mRNA and then compared as fold change relative to the 
average of mock infected controls. 
 
3.4. Induction of gene expression by viral infection in the CNS 
The above studies indicate that the identified genes may be useful markers of microglia and 
astrocyte activation in vitro. We next determined if any of these identified genes were induced in 
the brain following virus infection. We utilized two different mouse models of virus infection; a 
retrovirus (MuLV) infection model, where the primary cells infected are microglia and 
macrophages, and a La Crosse virus (LACV) infection, where the primary infected cells are 
neurons. In both model systems, gliosis is associated with pathogenesis. Of the ten genes examined, 
six were upregulated in the CNS in at least one model of virus infection (Fig. 3 and 4). Ifi202b 
mRNA was induced at higher levels with MuLV infection, while Traf1, AW11202010, Birc3, 
Gpr84,Cxcl11 and BC023105 were at higher levels in LACV infected mice. Interestingly, the two 
genes whose mRNAs were only upregulated in astrocytes, Elovl7 and Rapgef5, were not elevated in 
brain tissue following either virus infection. The increased gene expression of multiple mRNAs 
following LACV infection may be due the stronger neuroinflammatory response and greater 
inflammatory infiltrated observed in brain tissue from LACV-infected mice compared to MuLV-
infected mice. However, there was no clear association with any gene and the induction of 
activation of astrocytes and microglia, which is observed in both virus models. 
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Fig. 3: Analysis of mRNA expression in LACV-infected mice.  Brain tissues from mock- and 
LACV-infected mice were removed at the time points indicated, divided into two sagittal sections 
and snap frozen in liquid nitrogen and processed for RNA. Real-time quantitative RT-PCR analysis 
was performed using primers specific for Rapgef5, Elovl7, Cxcl11, BC023105, Ifi202B, Birc3, 
Traf1, Malt1, Gpr84, AW112010 and Gapdh. Data were calculated as gene expression relative to 
Gapdh expression (% of Gapdh expression) for each sam le.  
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Fig. 4: Analysis of mRNA expression in BE-infected mice.  Brain tissues from mock- and BE-
infected mice were removed at the time of apparent clinical disease (tremors, ataxia, seizures), 
divided into two sagittal sections and snap frozen in liquid nitrogen and processed for RNA. Real-
time quantitative RT-PCR analysis was performed using primers specific for Rapgef5, Elovl7, 
Cxcl11, BC023105, Ifi202B, Birc3, Traf1, Malt1, Gpr84, AW112010 and Gapdh. Data were 
calculated as gene expression relative to Gapdh expression (% of Gapdh expression) for each 
sample. 
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4. Discussion 
In the current study, we identified patterns of gene expression specific to astrocytes and microglia in 
the CNS following infection and/or inflammation. Astrocytes and microglia were purified from 
neonatal mice (1-2 day old) and these primary cultures were stimulated with TLR7 agonist, 
imiquimod. Gene expression was analyzed by microarray followed by quantitative PCR. The 
expression of genes involved in TLR7 signalling and production of proinflammatory cytokines and 
chemokines by astrocytes and microglia were compared. Quantitative comparison of astrocyte and 
microglia gene expression allowed for identification of all genes that are differentially 
overexpressed in each cell type. Based on microarray results we identified genes that were 
differentially up- and down-regulated in microglia only, in astrocytes only and in both cell type 
(Tab 5). 
One of the focuses of the current microarray study was to identify new markers of microglia and 
astrocyte activation that could be used for future studies. Therefore, we selected several genes and 
analyzed their expression by real-time PCR. For selection, we chose several genes from each 
category (microglia only, astrocyte only or both cells) including those with high expression as well 
as some of the genes that were on the lower spectrum of upregulation. We excluded the analysis of 
genes that were previously well characterized for their expression by microglia or astrocytes (e.g., 
Ccl5 and Nos2 for microglia as well as Ccl2 for astrocytes). 
Real-time PCR detection of gene expression was more sensitive than that observed with microarray 
when calculated as fold change relative to mock stimulated controls. This is most likely due to the 
amplification component of real-time PCR compared to the direct hybridization used for 
microarray. Genes expressed at very low levels may be at the lower limits of detection by 
hybridization, even after cellular activation. In contrast, the amplification cycles in real-time PCR 
allows the detection of genes that are expressed at very low levels. This may explain the detection 
of fold-increases of genes by real-time PCR, when these genes were not detected in that cell 
population by microarray analysis. Quantitative real-time PCR is the ideal tool for analyzing the 
expression of a focused panel of genes. Its high degree of reproducibility makes real-time RT-PCR 
the preferred choice for the simultaneous quantification of both rare and abundant genes in the same 
sample. For some differentially expressed genes, the PCR-array confirmed the microarray 
prediction, though not for all. Real-time PCR has often been used as a validation of microarray 
studies. However, there are variables between real-time PCR and microarray analysis, besides the 
amplification step, that could lead to disparate results. For example, the probes used in microarray 
and the primers used for real-time PCR can vary in their affinity for the gene of interest. This could 
produce differences in the level of amplification observed in these samples.  
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Variability in both biological and technical procedures can have a great impact on both microarray 
and real-time PCR results, the quality of RNA is essential to accurate results, as gene expression 
can be affected by carry-over of contaminating factors which can affect the reverse transcriptase 
used in both real-time PCR and RNA amplification procedures for microarray labelling.  
Gene expression data obtained from microarrays result were all of low intensity, overall, real-time 
PCR confirmed microarray results in the majority of genes analyzed. The relative change in 
expression for several genes as determined by microarray and real-time PCR are presented in Table 
5. Of the eight genes analyzed that were detected only in stimulated microglia, seven were found 
induced by greater than two fold by TLR7 stimulation of astrocytes and only five of these were 
upregulated at a much higher level in microglia than in astrocytes. This indicates that microglia 
generate a more robust gene response to TLR7 stimulation, in the overall level of mRNA 
upregulation, compared to astrocytes. One explanation for the differences in the responses to 
microglia and astrocytes following TLR7 activation could be microglia are activated earlier than 
astrocytes and subsequently activated microglia promote astrocytes activation with up-regulation of 
different genes. 
The current study analyzed different time point, at 3, 6, 12, 24, and 48h post stimulation, and found 
that there are fluctuations in genes expression at earlier and later time points. The ratio of fold gene 
expression relative to mock-stimulated controls was higher also at different time point with up-
regulation of subset of genes that peaks between 6-12 hours post-infection in microglia (Fig. 1). 
Low level induction of genes by TLR7 stimulation of astrocytes was observed. It is possible that the 
expressions of this genes begin early, immediately upon stimulation and indicates that microglia 
generate a more robust gene response to TLR7 stimulation, in the overall level of mRNA 
upregulation, compared to astrocytes. 
The gene expression of TLR7 activated astrocytes and microglia was also compared to cells 
stimulated with the TLR9 agonist, CpG-ODN 1826. Interestingly, the gene profile produced by 
agonist stimulation was similar between the type of TLR stimulation. A subset of genes were 
differentially regulated between TLR7 and TLR9 stimulation in microglia, including increased 
expression of Ifit1, Nlpr, Cd69, Tnfaip2 and BCO23105. The reasons for these differences are not 
clear, but it is possible that TLR9 stimulation results in distinct induction of different levels of 
transcription factors than TLR7 stimulation, resulting in some distinctions in gene expression. 
Upon TLR7/9 stimulation, we found that two of the four genes (Cxc1ll and BC023105) upregulated 
in astrocytes were also found to be upregulated in microglia, while the other two genes (Elovl7 and 
Rapgef5) remained upregulated greater than 2 fold in astrocytes only (Fig. 2). Thus, Elovl7 and 
Rapgef5 appear not to be induced by microglia and may be reliable markers to look at specific 
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astrocyte activation. In contrast, Cxcl11 and BC023105 are induced by activation in both cell types, 
but are most likely expressed at higher levels overall in astrocytes compared to microglia. 
Of the genes analysed for astrocytes, Cxcl11 generated the strongest upregulation as detected by 
real-time PCR (Table 4). Cxcl11, chemokine (C-X-C motif) ligand 11, also known as I-TAC 
(interferon-inducible T cell alpha chemoattractant)  was originally identified in IFN-β-treated 
astrocytes 
(118-120)
, which correlates with the high detectability in our cultures. However, 
immunohistochemistry analysis of brain tissues from virus infected mice showed only limited 
expression of Cxcl11 by astrocytes and high levels of expression by brain capillary endothelia cells 
(data  not shown). Thus, endothelia and astrocytes may both be important sources of Cxcl11 during 
virus infection in the brain, similar to the expression of CCL2 by both astrocytes and endothelia 
(data not shown). Cxcl11 is an important cytokine for the recruitment of T cells to the CNS. The 
production of Cxcl11 by both astrocytes and endothelia in the CNS may allow for greater control of 
T cell recruitment to the CNS. 
Only two genes (Elovl7 and Rapgef5) remained upregulated greater than 2 fold in astrocytes only. 
Elongation of very-long-chain fatty acids (Elovl7) is a member of the gene family that catalyze the 
elongation reaction of very-long-chain fatty acids (VLCFAs) 
(121)
. The ELOVLs catalyze the first, 
rate-limiting step of the VLCFA elongation cycle: condensation between the fatty acyl-CoA and 
malonyl-CoA to yield β-ketoacyl-CoA(122, 123). It has been shown that VLCFAs, docosanoic (C22:0, 
behenic acid)-, tetracosanoic (C24:0, lignoceric acid) and hexacosanoic acids (C26:0,cerotinic acid), 
exert a strong cytotoxic activity in oligodendrocytes and astrocytes derived from rat brain. VLCFAs 
also cause cell death of the myelin-producing oligodendrocytes and astrocytes 
(124)
. Increased Elovl7 
could lead to VLCFA accumulation, which results in demyelination and oxidative damage. Thus, 
the upregulation of Elovl7 by TLR stimulation of astrocytes could be a contributing factor to 
damage associated with astrogliosis and neurological damage. 
Ras-related GTP-binding proteins are molecular switch proteins which cycle between an inactive 
GDP-bound state and an active GTP-bound state. Activation is achieved by the exchange of tightly 
bound GDP for GTP. This reaction is very slow and is activated by guanine-nucleotide exchange 
factors (GEFs) or Rapgef5 
(125)
. Rapgef5 mediates the activation of Rap1 which is a member of the 
Ras GTPase family and is converted from inactive GDP-bound states to active GTP-bound 
(126, 127)
. 
Although we were able to detect Rapgef5 by real-time PCR in astrocyte cultures, we were unable to 
detect increased Rapgef5 in brain tissue from virus-infected mice. It is possible that Rapgef5 is 
more tightly controlled in vivo than it is in vitro.  Alternatively, Rapgef5 may be expressed by 
several cell types and therefore, increased expression of Rapgef5 in astrocytes may be masked by 
unchanged expression in other cell types. 
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Interestingly, Elovl7 and Rapgef5 were among the genes identified as being highly expressed in 
freshly-purified glia, but subsequent work revealed very few Elovl7 and Rapgef5 -expressing cells 
in the mouse models of virus infection. This could be due to many different reasons since the RNA 
analysed for virus infection was measured from whole brain samples which contain several other 
cell types besides astroglia. Furthermore, expression levels in vivo may differ from that in vitro.  
However, we can conclude from these data that neither Elovl7 or Rapgef5 are strong candidates for 
use as activation markers in astrocytes. 
Of the ten genes examined, six were upregulated in the CNS in at least one model of virus infection. 
Ifi202b mRNA was induced at higher levels with MuLV infection (Fig. 4), although this increase 
was not statistically significant, while Traf1, AW11202010, Birc3, Gpr84, Cxcl11 and BC023105 
were at higher levels in LACV infected mice (Fig 3). Increased  levels mRNA of Cxcl11, 
BC023105, Traf1, Birc3 and Gpr84 were first observed after 3 days post infection and remained 
high throughout the onset of neurological disease. The upregulation of these genes are indicative of 
the neuroinflammatory process associated with LACV infection, suggesting that these genes may be 
useful for the study of LACV-induced neurological disease.  
The increased gene expression of multiple mRNAs following LACV infection may be due the 
stronger neuroinflammatory response and greater inflammatory infiltrated observed in brain tissue 
from LACV-infected mice compared to MuLV-infected mice. However, there was no clear 
association with any gene and the induction of activation of astrocytes and microglia, which is 
observed in both virus models. 
Brain tissue from BE- and LACV-infected mice was analyzed for expression of some genes by 
immunohistochemistry. Tissue sections were analyzed for Gpr84, Malt1, Marco, Rapgef5, Cxcl11 
and Elovl7, but not positive cells were found (Data not shown). Interestingly, immunocytochemistry 
revealed expressions of these genes between 24 and 48 hours post stimulations with 5 µM 
imiquimod or 80 nM CpG-ODN 1826 (Data not shown) as detected by real-time PCR analysis. It is 
probable that inflammatory gene expression induced by TLR depends on an interplay between 
microglia and astrocytes, indeed astroglial-microglial cross talk is extremely important in glial cell 
activation. 
Under our experimental conditions, we demonstrated that microglia generate a much stronger 
response to TLR7 activation than astrocytes, with the upregulation and downregulation of 
substantially more genes in microglia than that observed in astrocytes. Subsequently, we identified 
genes that were uniquely upregulated by each cell type and examined these genes for upregulation 
by other factors including virus infection. These data provide a useful starting point to elucidate the 
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activation of astrocytes and microglia that will be useful in characterizing the cellular responses of 
these genes during infection or insult of the CNS, especially where TLR activation plays a role. 
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